Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 610

1.
2.

Role of prasugrel, a novel P2Y(12) receptor antagonist, in the management of acute coronary syndromes.

Baker WL, White CM.

Am J Cardiovasc Drugs. 2009;9(4):213-29. doi: 10.2165/1131209-000000000-00000. Review.

PMID:
19655817
3.

Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.

Thomas D, Giugliano RP.

Crit Pathw Cardiol. 2009 Mar;8(1):12-9. doi: 10.1097/HPC.0b013e318196bb46. Review.

PMID:
19258833
4.
5.

Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.

Capranzano P, Ferreiro JL, Angiolillo DJ.

Expert Rev Cardiovasc Ther. 2009 Apr;7(4):361-9. doi: 10.1586/erc.09.4. Review.

PMID:
19379060
6.

Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.

Martin MT, Spinler SA, Nutescu EA.

Clin Ther. 2011 Apr;33(4):425-42. doi: 10.1016/j.clinthera.2011.04.007. Review.

PMID:
21635989
7.

Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention.

Duggan ST, Keating GM.

Drugs. 2009 Aug 20;69(12):1707-26. doi: 10.2165/10484190-000000000-00000. Review.

PMID:
19678718
8.

The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.

Toth PP.

Postgrad Med. 2009 Jan;121(1):59-72. doi: 10.3810/pgm.2009.01.1955. Review.

PMID:
19179814
9.

Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.

Motovska Z, Kala P.

Clin Ther. 2008;30 Pt 2:2191-202. doi: 10.1016/j.clinthera.2008.12.001. Review.

PMID:
19281914
10.

Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.

Mousa SA, Jeske WP, Fareed J.

Clin Appl Thromb Hemost. 2010 Apr;16(2):170-6. doi: 10.1177/1076029609355589. Review.

PMID:
20299391
11.

Review of prasugrel for the secondary prevention of atherothrombosis.

Spinler SA, Rees C.

J Manag Care Pharm. 2009 Jun;15(5):383-95. Review.

12.

Clinical profile of prasugrel, a novel thienopyridine.

Angiolillo DJ, Bates ER, Bass TA.

Am Heart J. 2008 Aug;156(2 Suppl):S16-22. doi: 10.1016/j.ahj.2008.06.005. Review.

PMID:
18657682
13.

[Extent of platelet aggregation inhibition and clinical events: new evidence with prasugrel].

Abbate R, Crea F, De Servi S, Filippi E, Gensini GF, Golinos P, Savonitto S.

G Ital Cardiol (Rome). 2010 Feb;11(2):127-37. Review. Italian.

PMID:
20408476
14.

Prasugrel: a critical comparison with clopidogrel.

Reinhart KM, White CM, Baker WL.

Pharmacotherapy. 2009 Dec;29(12):1441-51. doi: 10.1592/phco.29.12.1441. Review.

PMID:
19947804
15.

Optimizing platelet P2Y12 inhibition for patients undergoing PCI.

Steinhubl S, Roe MT.

Cardiovasc Drug Rev. 2007 Summer;25(2):188-203. Review. Erratum in: Cardiovasc Drug Rev. 2007 Autumn;25(3):299.

PMID:
17614940
16.

Prasugrel: Clinical development and therapeutic application.

Guerra DR, Tcheng JE.

Adv Ther. 2009 Nov;26(11):999-1011. doi: 10.1007/s12325-009-0081-y. Epub 2009 Dec 17. Review.

PMID:
20020231
17.

Prasugrel development - claims and achievements.

Serebruany V, Shalito I, Kopyleva O.

Thromb Haemost. 2009 Jan;101(1):14-22. Review.

PMID:
19132184
18.

Thienopyridine antiplatelet agents: focus on prasugrel.

Freeman MK.

Consult Pharm. 2010 Apr;25(4):241-57. doi: 10.4140/TCP.n.2010.241. Review.

PMID:
20511177
19.

Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.

Greenhalgh J, Bagust A, Boland A, Saborido CM, Fleeman N, McLeod C, Dundar Y, Dickson R, Proudlove C, Kolamunnage-Dona R, Fisher M.

Health Technol Assess. 2010 May;14 Suppl 1:31-8. doi: 10.3310/hta14Suppl1/05. Review.

20.

Critical review of prasugrel for formulary decision makers.

Schafer JA, Kjesbo NK, Gleason PP.

J Manag Care Pharm. 2009 May;15(4):335-43. Review.

Items per page

Supplemental Content

Write to the Help Desk